Impact of Suvorexant on Sympathetic Nerve Activity and Baroreflex Function in Chronic Insomnia

  • Interventional
  • Recruiting
  • NCT03768713
Eligibility Details Visit Clinicaltrials.gov

A Randomized, Double-Blind, Placebo-Controlled Study to Determine the Effect of Suvorexant (Belsomra®) on Sympathetic Neural Activity and Baroreflex Function in Patients With Chronic Insomnia

This study aims to evaluate the effect of Suvorexant on sympathetic nerve activity and baroreflex function in subject with chronic insomnia. The investigator's central hypothesis is that Suvorexant will reduce sympathetic nerve activity and improve baroreflex function when compared to placebo.

This study will utilize a randomized, double-blind, placebo-controlled experimental approach to determine the effects of 8-wk treatment with Suvorexant (Belsomra®) on sympathetic nerve activity and baroreflex function in male and female subjects with chronic insomnia. The study will utilize established techniques for assessing sleep (polysomnography), blood pressure (sphygmomanometer and beat-to-beat finger plethysmography), and peripheral sympathetic nerve activity (microneurography). The study will stratify enrollment based upon both age and sex (i.e., male vs. female) because these two covariates are known to influence sympathetic nerve activity and baroreflex function.

Gender
All

Age Group
18 Years to 65 Years

Accepting Healthy Volunteers?
No

Inclusion Criteria:

         - Minimum 3 months of clinically diagnosed insomnia

         - Body mass index ≤35 kg/m2

         - Insomnia Severity Index (ISI) > 14 arbitrary units (i.e., moderate-to-severe insomnia)

         - Pittsburgh Sleep Quality Index (PSQI) > 5 arbitrary units

         - Habitual self-report and objectively-assessed (i.e., 14-day actigraphy) sleep duration of <6.5 hours

         - Pre-menopausal women must have regular menstrual cycles (~26-30 day cycles) and will be scheduled for microneurography 2-7 days after menstruation to consistently test during the early follicular phase (or low-hormone phase in women on contraceptives)

        Exclusion Criteria:

         - Current or prior treatment of Suvorexant.

         - Obstructive sleep apnea defined as an apnea-hypopnea index > 15 using an FDA approved home sleep apnea screening devices as used in routine clinical practice.

         - Participants without evidence of clinically significant obstructive sleep apnea on the screening test will undergo an overnight in-laboratory polysomnography to confirm absence of sleep apnea (apnea-hypopnea index of ≥ 10 episodes per hour) and to exclude other sleep disorders (e.g. periodic limb movement arousal index of ≥ 5 episodes per hour)

         - Circadian rhythm sleep disorders

         - History of meeting DSM-V criteria of major psychiatric disorder

         - Have been clinically-diagnosed with diabetes, cardiovascular disease, or any other unstable or serious medical condition.

         - Current, or use within past month, of psychoactive (other than stable treatment with antidepressant), hypnotic, stimulant or analgesic medication (except occasional non-narcotic analgesics), beta blockers, or alpha blockers

         - Shift work or other types of self-imposed irregular sleep schedules

         - Habitual smoking (6 or more cigarettes per week)

         - Habitual alcohol consumption (more than 2 alcoholic drinks per day)

         - Breastfeeding or pregnancy
  • Chronic Insomnia

At a Glance

National Government IDNCT03768713

IRB#IRB18-0455

Lead SponsorMichigan Technological University

Lead PhysicianBabak Mokhlesi

Collaborator(s)N/A

EligibilityAll
18 Years to 65 Years
Recruiting